| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To provide recombinant anti-VLA-4 antibody molecules, useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease, and useful in methods of diagnosing and localizing sites of inflammation. <P>SOLUTION: The humanized recombinant anti-VLA-4 antibodies has the specificity to VLA4 and antigen-binding sites, wherein at least one of complementarity determining region (CDR) of variable domain is derived from non-humanized anti-VLA-4 antibodies, and the antibody has a potency of about 20 to 100% based on the potency of mouse HP1/2 monoclonal antibody. <P>COPYRIGHT: (C)2008,JPO&INPIT</p> |
